

FILE 'HOME' ENTERED AT 11:56:24 ON 28 SEP 2002

=> file chemistry  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'AGRICOLA' ENTERED AT 11:56:42 ON 28 SEP 2002

FILE 'ALUMINIUM' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (c) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUIRE' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 US Environmental Protection Agency (EPA)

FILE 'BABS' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'BIOCOMMERCE' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All  
rights reserved

FILE 'BIOTECHNO' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'CAOLD' ENTERED AT 11:56:42 ON 28 SEP 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 11:56:42 ON 28 SEP 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (c) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEABA-VTB' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (c) 2002 DECHEMA eV

FILE 'CEN' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CERAB' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CIN' ENTERED AT 11:56:42 ON 28 SEP 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 11:56:42 ON 28 SEP 2002  
Compendex Compilation and Indexing (C) 2002



Elsevier Engineering Information Inc (EEI). All rights reserved.  
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'CONFSCI' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'COPPERLIT' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Copper Development Association Inc. (CDA)

FILE 'CORROSION' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'DKILIT' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (c) 2002 FIZ Karlsruhe

FILE 'ENCOMPLIT' ENTERED AT 11:56:42 ON 28 SEP 2002  
EnComplit compilation and indexing (C) 2002  
Elsevier Engineering Information Inc. All rights reserved.

FILE 'ENCOMPLIT2' ENTERED AT 11:56:42 ON 28 SEP 2002  
EnComplit2 compilation and indexing (C) 2002  
Elsevier Engineering Information Inc. All rights reserved.

FILE 'FEDRIP' ENTERED AT 11:56:42 ON 28 SEP 2002

FILE 'GENBANK' ENTERED AT 11:56:42 ON 28 SEP 2002

FILE 'INSPEC' ENTERED AT 11:56:42 ON 28 SEP 2002  
Compiled and produced by the IEE in association with FIZ KARLSRUHE  
COPYRIGHT 2002 (c) INSTITUTION OF ELECTRICAL ENGINEERS (IEE)

FILE 'INSPHYS' ENTERED AT 11:56:42 ON 28 SEP 2002  
Compiled and produced by the IEE in association with FIZ KARLSRUHE  
COPYRIGHT 2002 (c) INSTITUTION OF ELECTRICAL ENGINEERS (IEE)

FILE 'INVESTEXT' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'IPA' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics Chemists

FILE 'METADEX' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (c) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'NAPRALERT' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,  
University of Illinois at Chicago.

FILE 'NIOSHTIC' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 11:56:42 ON 28 SEP 2002  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2002)

FILE 'PAPERCHEM2' ENTERED AT 11:56:42 ON 28 SEP 2002  
Paperchem2 compilation and indexing (C) 2002



Elsevier Engineering Information Inc. All rights reserved.

FILE 'PASCAL' ENTERED AT 11:56:42 ON 28 SEP 2002  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 RAPRA Technology Ltd.

FILE 'RUSSCI' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Andrigal Ltd.

FILE 'SCISEARCH' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'TULSA' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 The University of Tulsa (UTULSA)

FILE 'TULSA2' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 The University of Tulsa (UTULSA)

FILE 'USAN' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 U.S. Pharmacopeial Convention, Inc. (USPC)

FILE 'WELDASEARCH' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (c) 2002 The Welding Institute (TWI)

FILE 'WSCA' ENTERED AT 11:56:42 ON 28 SEP 2002  
COPYRIGHT (C) 2002 PAINT RESEARCH

=> polysaccharide

=> s polysaccharide

40 FILES SEARCHED...

L1 239378 POLYSACCHARIDE

=> s li and glycosaminoglycan

39 FILES SEARCHED...

L2 40 LI AND GLYCOSAMINOGLYCAN

=> s l2 and K5

L3 1 L2 AND K5

=> dis l3 bib abs

L3 ANSWER 1 OF 1 SCISEARCH COPYRIGHT 2002 ISI (R)  
AN 97:816986 SCISEARCH  
GA The Genuine Article (R) Number: YD473  
TI Biosynthesis of heparin/heparan sulfate - DNA cloning and expression of  
D-glucuronyl C5-epimerase from bovine lung  
AU Li J P (Reprint); HagnerMcWhirter A; Kjellen L; Palgi J; Jalkanen M;  
Lindahl U  
CS UNIV UPPSALA, DEPT MED & PHYSIOL CHEM, POB 575; S-75123 UPPSALA, SWEDEN  
(Reprint); SWEDISH UNIV AGR SCI, CTR BIOMED, DEPT VET MED CHEM, S-75123  
UPPSALA, SWEDEN; UNIV TURKU, CTR BIOTECHNOL, FIN-20520 TURKU, FINLAND; ABO  
AKAD UNIV, FIN-20520 TURKU, FINLAND  
CYA SWEDEN; FINLAND  
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (31 OCT 1997) Vol. 272, No. 44, pp.  
28158-28163.  
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE



PIKE, BETHESDA, MD 20814.

ISSN: 0021-9258.

DT Article; Journal

FS LIFE

LA English

REC Reference Count: 33

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB Glucuronyl C5-epimerases catalyze the conversion of D-glucuronic acid (GlcUA) to L-iduronic acid (IdceA) units during the biosynthesis of **glycosaminoglycans**. An epimerase implicated in the generation of heparin/heparan sulfate was previously purified to homogeneity from bovine liver (Campbell, P., Hannesson, H. H., Sandback, D., Roden, L., Lindahl, U., and Li, J.-p, (1994) J. Biol. Chem. 269, 2695-26958). The present report describes the molecular cloning and functional expression of the lung enzyme, The cloned enzyme contains 444 amino acid residues and has a molecular mass of 49,905 Da, N-terminal sequence analysis of the isolated liver enzyme showed this species to be a truncated form lacking a 73-residue N-terminal domain of the deduced amino acid sequence.

The coding cDNA insert was cloned into a baculovirus expression vector and expressed in Sf9 insect cells, Cells infected with recombinant epimerase showed a 20-30-fold increase in enzyme activity, measured as release of (H2O)-H-3 from a polysaccharide substrate containing C5-H-3-labeled hexuronic acid units. Furthermore, incubation of the expressed protein with the appropriate (GlcUA-GlcNSO(3))(n) substrate resulted in conversion of similar to 20% of the GlcUA units into IdceA residues, Northern analysis implicated two epimerase transcripts in both bovine lung and liver tissues, a dominant similar to 9-kilobase (kb) mRNA and a minor similar to 5-kb species, Mouse mastocytoma cells showed only the similar to 5-kb transcript. A comparison of the cloned epimerase with the enzymes catalyzing an analogous reaction in alginate biosynthesis revealed no apparent amino acid sequence similarity.

=> s l1 and K5

42 FILES SEARCHED...

L4 351 L1 AND K5

=> s l4 and epimer?

L5 33 L4 AND EPIMER?

=> s l5 and enzyme

36 FILES SEARCHED...

L6 20 L5 AND ENZYME

=> s l6 and immobil?

37 FILES SEARCHED...

L7 5 L6 AND IMMOBIL?

=> dis l7 1-5 bib abs

L7 ANSWER 1 OF 5 BIOTECHNO COPYRIGHT 2002 Elsevier Science B.V.

AN 1994:24332896 BIOTECHNO

TI Biosynthesis of heparin/heparan sulfate. Purification of the D-glucuronyl C-5 **epimerase** from bovine liver

AU Campbell P.; Hannesson H.H.; Sandback D.; Roden L.; Lindahl U.; Li J.-P.

CS Dept. of Medical/Physiological Chem., Biomedical Center, University of Uppsala,S-751 23 Uppsala, Sweden.

SO Journal of Biological Chemistry, (1994), 269/43 (26953-26958)

CODEN: JBCHA3 ISSN: 0021-9258

DT Journal; Article

CY United States

LA English

SL English

AB The D-glucuronyl C-5 **epimerase** involved in the biosynthesis of



heparin/heparan sulfate was purified from the high speed supernatant fraction of a homogenate of bovine liver by chromatography on **immobilized** O-desulfated heparin, red Sepharose, phenyl Sepharose, and concanavalin A-Sepharose. After close to 1 million-fold purification, in 10-15% yield, the product gave a single band on SDS-polyacrylamide gel electrophoresis with silver staining and had a mobility corresponding to an M(r) of .sim.52,000. Since the **epimerase** assay used in the course of purification was based on release of tritium, as .cents..<sup>3</sup>H!H.sub.2O, from a .cents.5-..<sup>3</sup>H!uronyl-labeled substrate, it was important to establish that the purified **enzyme** did indeed catalyze the actual conversion of D-glucuronyl to L-iduronyl residues. Upon incubation of the purified **enzyme** with .sup.3H-labeled heparosan N-sulfate, prepared by metabolic labeling (with D-..<sup>1</sup>-..<sup>3</sup>H!glucose) of a capsular **polysaccharide** from Escherichia coli **K5** and subsequent chemical partial N-deacetylation and N-sulfation, approximately 30% of the D-glucuronyl residues located between two N-sulfated glucosamine units were converted to L-iduronyl units.

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS

AN 2002:392262 CAPLUS

DN 136:380105

TI Glycosaminoglycans derived from **k5 polysaccharide** having high anticoagulant and antithrombotic activities and process for their preparation

IN Oreste, Pasqua; Zoppetti, Giorgio

PA Italy

SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 738,879.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002062019	A1	20020523	US 2001-950003	20010912
	IT 2000MI0665	A1	20011001	IT 2000-MI665	20000330
	WO 2002050125	A2	20020627	WO 2001-IB2492	20011217
	WO 2002050125	A3	20020822		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI IT 2000-MI665 A 20000330

US 2000-738879 A2 20001218

US 2001-950003 A 20010912

AB Glycosaminoglycans derived from **K5 polysaccharide** having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified **K5 polysaccharide** by a process comprising the steps of N-deacetylation/N-sulfation, C5 **epimerization**, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymn., in which said **epimerization** is performed with the use of the **enzyme** glucuronosyl C5 **epimerase** in soln. or in **immobilized** form in the presence of divalent cations. New, particularly interesting antithrombin compds. are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerization.



L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS  
AN 2001:730838 CAPLUS  
DN 135:267246

TI Glycosaminoglycans derived from the **k5 polysaccharide**  
having high anticoagulant and antithrombotic activity and process for  
their preparation

IN Zoppetti, Giorgio; Oreste, Pasqua; Cipolletti, Giovanni

PA Inalco S.p.A., Italy

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072848	A1	20011004	WO 2001-EP3461	20010327
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	IT 2000MI0665	A1	20011001	IT 2000-MI665	20000330
PRAI	IT 2000-MI665	A	20000330		

AB Glycosaminoglycans derived from the **K5 polysaccharide**  
having high anticoagulant and antithrombotic activity obtained by a  
process comprising the prepn. of the **K5 polysaccharide**  
from Escherichia coli, N-deacetylation/N-sulfation, C-5  
**epimerization**, supersulfation, selective O-desulfation, selective  
6-O sulfation and N-sulfation, wherein said **epimerization** is  
carried out using the glucuronosyl C-5 **epimerase enzyme**  
in soln. or in **immobilized** form in presence of specific divalent  
cations.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS  
AN 1994:624763 CAPLUS  
DN 121:224763

TI Biosynthesis of heparin/heparan sulfate. Purification of the D-glucuronyl  
C-5 **epimerase** from bovine liver

AU Campbell, Patrick; Hanneson, Helgi H.; Sandbaeck, Dagmar; Roden,  
Lennart; Lindahl, Ulf; Li, Jin-ping

CS Univ. Alabama, Birmingham, AL, 35294, USA

SO Journal of Biological Chemistry (1994), 269(43), 26953-8

CODEN: JBCHA3; ISSN: 0021-9258

DT Journal

LA English

AB The D-glucuronyl C-5 **epimerase** involved in the biosynthesis of  
heparin/heparan sulfate was purified from the high speed supernatant  
fraction of a homogenate of bovine liver by chromatog. on  
**immobilized** O-desulfate heparin, red Sepharose, Ph Sepharose, and  
Con A-Sepharose. After close to 1 million-fold purifn., 10-15% yield, the  
product gave a single band on SDS-PAGE with silver staining and had a  
mobility corresponding to an Mr of .apprx.52,000. Since the  
**epimerase** assay used in the course of purifn. was based on release  
of tritium, as [3H]H2O, from a [5-3H]uronyl-labeled substrate, it was  
important to establish that the purified **enzyme** did indeed  
catalyze the actual conversion of D-glucuronyl to L-iduronyl residues.  
Upon incubation of the purified **enzyme** with 3H-labeled heparosan



N-sulfate, prep'd. by metabolic labeling (with D-[1-3H]glucose) of a capsular **polysaccharide** from Escherichia coli **K5** and subsequent chem. partial N-deacetylation and N-sulfation, approx. 30% of the D-glucuronyl residues located between two N-sulfated glucosamine units were converted to L-iduronyl units.

L7 ANSWER 5 OF 5 SCISEARCH COPYRIGHT 2002 ISI (R)  
AN 94:733790 SCISEARCH  
GA The Genuine Article (R) Number: PQ931  
TI BIOSYNTHESIS OF HEPARIN/HEPARAN SULFATE - PURIFICATION OF THE D-GLUCURONYL C-5 **EPIMERASE** FROM BOVINE LIVER  
AU CAMPBELL P; HANNESSON H H; SANDBACK D; RODEN L; LINDAHL U; LI J P  
(Reprint)  
CS UNIV UPPSALA, DEPT MED & PHYSIOL CHEM, BOX 575, S-75123 UPPSALA, SWEDEN  
(Reprint); UNIV UPPSALA, DEPT MED & PHYSIOL CHEM, S-75123 UPPSALA, SWEDEN;  
UNIV ALABAMA, BIRMINGHAM, AL, 35294  
CYA SWEDEN; USA  
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (28 OCT 1994) Vol. 269, No. 43, pp.  
26953-26958.  
ISSN: 0021-9258.  
DT Article; Journal  
FS LIFE  
LA ENGLISH  
REC Reference Count: 21

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB The D-glucuronyl C-5 **epimerase** involved in the biosynthesis of heparin/heparan sulfate was purified from the high speed supernatant fraction of a homogenate of bovine liver by chromatography on **immobilized** O-desulfated heparin, red Sepharose, phenyl Sepharose, and concanavalin A-Sepharose. After close to 1 million-fold purification, in 10-15% yield, the product gave a single band on SDS-polyacrylamide gel electrophoresis with silver staining and had a mobility corresponding to an M(r) of similar to 52,000. Since the **epimerase** assay used in the course of purification was based on release of tritium, as [H-3]H<sub>2</sub>O, from a [5-H-3]uronyl-labeled substrate, it was important to establish that the purified **enzyme** did indeed catalyze the actual conversion of D-glucuronyl to L-iduronyl residues. Upon incubation of the purified **enzyme** with H-3-labeled heparosan N-sulfate, prepared by metabolic labeling (with D-[1-H-3]glucose) of a capsular **polysaccharide** from Escherichia coli **K5** and subsequent chemical partial N-deacetylation and N-sulfation, approximately 30% of the D-glucuronyl residues located between two N-sulfated glucosamine units were converted to L-iduronyl units.

=> dis.hist

(FILE 'HOME' ENTERED AT 11:56:24 ON 28 SEP 2002)

FILE 'AGRICOLA, ALUMINIUM, ANABSTR, AQUIRE, BABS, BIOCOMMERCE, BIOTECHNO, CABA, CAOLD, CAPLUS, CBNB, CEABA-VTB, CEN, CERAB, CIN, COMPENDEX, CONFSCI, COPPERLIT, CORROSION, DKILIT, ENCOMPLIT, ENCOMPLIT2, FEDRIP, GENBANK, INSPEC, INSPHYS, INVESTEXT, IPA, ...' ENTERED AT 11:56:42 ON 28 SEP 2002

L1 239378 S POLYSACCHARIDE  
L2 40 S LI AND GLYCOSAMINOGLYCAN  
L3 1 S L2 AND K5  
L4 351 S L1 AND K5  
L5 33 S L4 AND EPIMER?  
L6 20 S L5 AND ENZYME  
L7 5 S L6 AND IMMOBIL?

=> s l2 and composition  
35 FILES SEARCHED...



L8 1 L2 AND COMPOSITION

=> dis l8 bib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS  
AN 2002:532818 CAPLUS  
TI Extracellular matrix **composition** of full-thickness defect repair  
tissue is little influenced by exercise in rat articular cartilage  
AU Espanha, M. Margarida; Lammi, Pirkko E.; Hyttinen, Mika M.; Lammi, Mikko  
J.; Helminen, Heikki J.  
CS Faculty of Human Kinetics, Technical University of Lisboa, Lisbon, Port.  
SO Connective Tissue Research (2001), 42(2), 97-109  
CODEN: CVTRBC; ISSN: 0300-8207  
PB Gordon & Breach Science Publishers  
DT Journal  
LA English  
AB Full-thickness articular cartilage defects in the femoral condyles of  
adult rats were examd. four and eight weeks after injury. Quant.  
polarized light microscopic anal. showed that birefringence of the tissue  
in the central repair area increased more in rats exercised on a  
treadmill. **Glycosaminoglycan** content in the repair tissue was  
also higher than in the intermittent active motion group at four weeks  
after injury, but by eight weeks the levels were similar in both groups.  
No normal-looking articular cartilage was formed in the lesions, and only  
in one animal type **1I** collagen was obsd. in the superficial zone  
of repair tissue. No 3B3(-) antigenicity of the proteoglycans was seen  
during repair. In conclusion, exercise minimally modified the repair of  
full-thickness articular cartilage defects in adult rats. The repair in  
the exercised group may occur slightly faster in the early stages but no  
difference was seen at the eight week time interval between the exercised  
and the intermittently active group.  
RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis hist

(FILE 'HOME' ENTERED AT 11:56:24 ON 28 SEP 2002)

FILE 'AGRICOLA, ALUMINIUM, ANABSTR, AQUIRE, BABS, BIOCOMMERCE, BIOTECHNO,  
CABA, CAOLD, CAPLUS, CBNB, CEABA-VTB, CEN, CERAB, CIN, COMPENDEX,  
CONFSCI, COPPERLIT, CORROSION, DKILIT, ENCOMPLIT, ENCOMPLIT2, FEDRIP,  
GENBANK, INSPEC, INSPHYS, INVESTEXT, IPA, ...' ENTERED AT 11:56:42 ON 28  
SEP 2002

L1 239378 S POLYSACCHARIDE  
L2 40 S L1 AND GLYCOSAMINOGLYCAN  
L3 1 S L2 AND K5  
L4 351 S L1 AND K5  
L5 33 S L4 AND EPIMER?  
L6 20 S L5 AND ENZYME  
L7 5 S L6 AND IMMOBIL?  
L8 1 S L2 AND COMPOSITION

=> s l4 and composition

39 FILES SEARCHED...

L9 13 L4 AND COMPOSITION

=> s l9 and glycosaminoglycan

42 FILES SEARCHED...

L10 0 L9 AND GLYCOSAMINOGLYCAN

=> s l9 and carrier

39 FILES SEARCHED...

L11 0 L9 AND CARRIER



=> s l9 and ion?  
20 FILES SEARCHED...  
36 FILES SEARCHED...  
L12 1 L9 AND ION?

=> dis l12 bib abs

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS  
AN 1984:2544 CAPLUS  
DN 100:2544  
TI Assay of N-acetylheparosan deacetylase with a capsular  
**polysaccharide** from Escherichia coli K5 as substrate  
AU Navia, Juan Luis; Riesenfeld, Johan; Vann, Willie F.; Lindahl, Ulf; Roden,  
Lennart  
CS Inst. Dent. Res., Univ. Alabama, Birmingham, AL, 35294, USA  
SO Anal. Biochem. (1983), 135(1), 134-40  
CODEN: ANBCA2; ISSN: 0003-2697  
DT Journal  
LA English  
AB A new substrate for N-acetylheparosan deacetylase was prepd. The capsular  
**polysaccharide** from E. coli 010:K5:H4, which is  
structurally identical to N-acetylheparosan, was partially N-deacetylated  
by hydrazinolysis and was then radioactively labeled by N-acetylation with  
[3H]acetic anhydride. Upon incubation of the labeled  
**polysaccharide** with microsomes from the Furth mastocytoma,  
[3H]acetyl groups were released, demonstrating that the bacterial  
**polysaccharide** was a substrate for the N-deacetylase. Reaction  
conditions were established which permitted the quant. assay of  
N-deacetylase activity; a Km of 74 mg **polysaccharide**/L was detd.  
which corresponds to 2.1 .times. 10-4M, expressed as concn. of uronic  
acid; the Vmax was 3.4 nmol/mg protein/L. In confirmation of previous  
results, it was obsd. (1) that the reaction was stimulated by  
3'-phosphoadenylylsulfate (up to a max. of 45% at a concn. of 0.5 mM),  
suggesting that N-sulfation occurred which facilitated continued action of  
the N-deacetylase, and (2) that NaCl and KCl inhibited the enzyme, with  
50% redn. of activity at a concn. of 25 mM. In the course of this work, a  
simple, single-vial assay procedure was used. Released [3H]acetate was  
extd. from the acidified reaction mixt. with a toluene- or xylene-based  
scintillation fluid contg. 10% isoamyl alc. and measured directly by  
scintillation spectrometry.

=> s glycosaminoglycans  
L13 23302 GLYCOSAMINOGLYCANS

=> s l13 and K5  
L14 47 L13 AND K5

=> s l14 and process  
25 FILES SEARCHED...  
L15 7 L14 AND PROCESS

=> s l15 deacetyla?  
MISSING OPERATOR L15 DEACETYLA?  
The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> s l15 and deacetyla?  
L16 6 L15 AND DEACETYLA?

=> s l16 and N-sulfat?  
75% OF LIMIT FOR L#S REACHED  
26 FILES SEARCHED...



L17 6 L16 AND N-SULFAT?

=> dis 117 1-6 bib abs

L17 ANSWER 1 OF 6 BIOTECHNO COPYRIGHT 2002 Elsevier Science B.V.  
AN 2001:32989368 BIOTECHNO  
TI Toward a biotechnological heparin through combined chemical and enzymatic  
modification of the Escherichia coli **K5** polysaccharide  
AU Naggi A.; Torri G.; Casu B.; Oreste P.; Zoppetti G.; Li J.P.; Lindahl U.  
CS Prof. B. Casu, G. Ronzoni Research Institute, via G. Colombo, 81-20133  
Milano, Italy.  
E-mail: casu@ronzoni.it  
SO Seminars in Thrombosis and Hemostasis, (2001), 27/5 (437-443), 26  
reference(s)  
CODEN: STHMBV ISSN: 0094-6176  
DT Journal; General Review  
CY United States  
LA English  
SL English  
AB A **process** to generate **glycosaminoglycans** with  
heparin- and heparan sulfate-like sequences from the Escherichia coli  
**K5** capsular polysaccharide is described. This polymer has the  
same structure as N-acetylheparosan, the precursor in heparin/heparan  
sulfate biosynthesis. The **process** involves chemical N-  
**deacetylation** and **N-sulfation**, enzymatic,  
conversion of up to 60% of the D-glucuronic acid to L-iduronic acid  
residues, and chemical O-sulfation. Because direct sulfation afforded  
unwanted 3-O-sulfated (instead of 2-O-sulfated) iduronic acid residues, a  
strategy involving graded solvolytic desulfation of chemically  
oversulfated C5-epimerized sulfaminoheparosans was assessed using  
persulfated heparin and heparan sulfate as model compounds. The  
O-desulfation **process** was shown to increase the anti-factor Xa  
activity of oversulfated heparin.

L17 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2002 ACS  
AN 2002:392262 CAPLUS  
DN 136:380105  
TI **Glycosaminoglycans** derived from **k5** polysaccharide  
having high anticoagulant and antithrombotic activities and  
**process** for their preparation  
IN Oreste, Pasqua; Zoppetti, Giorgio  
PA Italy  
SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 738,879.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002062019	A1	20020523	US 2001-950003	20010912
	IT 2000MI0665	A1	20011001	IT 2000-MI665	20000330
	WO 2002050125	A2	20020627	WO 2001-IB2492	20011217
	WO 2002050125	A3	20020822		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	IT 2000-MI665	A	20000330		



US 2000-738879 A2 20001218  
US 2001-950003 A 20010912

AB **Glycosaminoglycans** derived from **K5** polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified **K5** polysaccharide by a **process** comprising the steps of **N-deacetylation/N-sulfation**, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, **N-sulfation**, and optional depolymn., in which said epimerization is performed with the use of the enzyme glucuronosyl C5 epimerase in soln. or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compds. are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final **N-sulfation** step to depolymerization.

L17 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS

AN 2001:840398 CAPLUS

DN 136:167613

TI Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli **K5** polysaccharide

AU Naggi, Annamaria; Torri, Giangiacomo; Casu, Benito; Oreste, Pasqua; Zoppetti, Giorgio; Li, Jin-Ping; Lindahl, Ulf

CS G. Ronzoni Institute for Chemical and Biochemical Research, Milan, Italy

SO Seminars in Thrombosis and Hemostasis (2001), 27(5), 437-443 *data not good*  
CODEN: STHMBV; ISSN: 0094-6176

PB Thieme Medical Publishers, Inc.

DT Journal

LA English

AB A **process** to generate **glycosaminoglycans** with heparin and heparan sulfate-like sequences from the Escherichia coli **K5** capsular polysaccharide is described. This polymer has the same structure as N-acetylheparosan, the precursor in heparin/heparan sulfate biosynthesis. The **process** involves chem. **N-deacetylation** and **N-sulfation**, enzymic conversion of up to 60% of the D-glucuronic acid to L-iduronic acid residues, and chem. O-sulfation. Because direct sulfation afforded unwanted 3-O-sulfated (instead of 2-O-sulfated) iduronic acid residues, a strategy involving graded solvolytic desulfation of chem. over-sulfated C5-epimerized sulfaminoheparosans was assessed using persulfated heparin and heparan sulfate as model compds. The O-desulfation **process** was shown to increase the anti-factor Xa activity of over-sulfated heparin.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS

AN 2001:730838 CAPLUS

DN 135:267246

TI **Glycosaminoglycans** derived from the **k5** polysaccharide having high anticoagulant and antithrombotic activity and **process** for their preparation

IN Zoppetti, Giorgio; Oreste, Pasqua; Cipolletti, Giovanni

PA Inalco S.p.A., Italy

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072848	A1	20011004	WO 2001-EP3461	20010327
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,				



HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,  
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,  
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT 2000MI0665 A1 20011001 IT 2000-MI665 20000330

PRAI IT 2000-MI665 A 20000330

AB **Glycosaminoglycans** derived from the **K5** polysaccharide having high anticoagulant and antithrombotic activity obtained by a **process** comprising the prepn. of the **K5** polysaccharide from *Escherichia coli*, **N-deacetylation/N-sulfation**, C-5 epimerization, supersulfation, selective O-desulfation, selective 6-O sulfation and **N-sulfation**, wherein said epimerization is carried out using the glucuronosyl C-5 epimerase enzyme in soln. or in immobilized form in presence of specific divalent cations.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 6 PASCAL COPYRIGHT 2002 INIST-CNRS. ALL RIGHTS RESERVED.  
 AN 2002-0168335 PASCAL  
 CP Copyright .COPYRGT. 2002 INIST-CNRS. All rights reserved.  
 TIEN Toward a biotechnological heparin through combined chemical and enzymatic modification of the *Escherichia coli* **K5** polysaccharide Glycoaminoglycans  
 AU NAGGI Annamaria; TORRI Giangiacomo; CASU Benito; ORESTE Pasqua; ZOPPETTI Giorgio; LI Jin-Ping; LINDAHL Ulf  
 HARENBERG Job (ed.)  
 CS G. Ronzoni Institute for Chemical and Biochemical Research, Milan, Italy; Inalco, Montale, Pistoia, Italy; Department of Medical Biochemical Microbiology, University of Uppsala, Uppsala, Sweden  
 SO Seminars in thrombosis and hemostasis, (2001), 27(5), 437-443, 26 refs. ISSN: 0094-6176 CODEN: STHMBV  
 DT Journal  
 BL Analytic  
 CY United States  
 LA English  
 AV INIST-17786, 354000094741730010  
 CP Copyright .COPYRGT. 2002 INIST-CNRS. All rights reserved.  
 AB A **process** to generate **glycosaminoglycans** with heparin- and heparan sulfate-like sequences from the *Escherichia coli* **K5** capsular polysaccharide is described. This polymer has the same structure as N-acetylheparosan, the precursor in heparin/ heparan sulfate biosynthesis. The **process** involves chemical **N-deacetylation** and **N-sulfation**, enzymatic conversion of up to 60% of the D-glucuronic acid to L-iduronic acid residues, and chemical O-sulfation. Because direct sulfation afforded unwanted 3-O-sulfated (instead of 2-O-sulfated) iduronic acid residues, a strategy involving graded solvolytic desulfation of chemically oversulfated C5-epimerized sulfaminoheparosans was assessed using persulfated heparin and heparan sulfate as model compounds. The O-desulfation **process** was shown to increase the anti-factor Xa activity of oversulfated heparin.

L17 ANSWER 6 OF 6 SCISEARCH COPYRIGHT 2002 ISI (R)  
 AN 2001:876964 SCISEARCH  
 GA The Genuine Article (R) Number: 486YG  
 TI Toward a biotechnological heparin through combined chemical and enzymatic modification of the *Escherichia coli* **K5** polysaccharide  
 AU Naggi A; Torri G; Casu B (Reprint); Oreste P; Zoppetti G; Li J P; Lindahl U  
 CS G Ronzoni Res Inst, Via G Colombo, 81, I-20133 Milan, Italy (Reprint); G



Ronzoni Res Inst, I-20133 Milan, Italy; G Ronzoni Inst Chem & Biochem Res, Milan, Italy; Inalco, Montale, Pistoia, Italy; Univ Uppsala, Dept Med Biochem Microbiol, S-75105 Uppsala, Sweden

CYA Italy; Sweden

SO SEMINARS IN THROMBOSIS AND HEMOSTASIS, (OCT 2001) Vol. 27, No. 5, pp. 437-443.

Publisher: THIEME MEDICAL PUBL INC, 333 SEVENTH AVE, NEW YORK, NY 10001 USA.

ISSN: 0094-6176.

DT Article; Journal

LA English

REC Reference Count: 26

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB A **process** to generate **glycosaminoglycans** with heparin- and heparan sulfate-like sequences from the Escherichia coli K5 capsular polysaccharide is described. This polymer has the same structure as N-acetylheparosan, the precursor in heparin/ heparan sulfate biosynthesis. The **process** involves chemical N-**deacetylation** and N-**sulfation**, enzymatic conversion of up to 60% of the D-glucuronic acid to L-iduronic acid residues, and chemical O-sulfation. Because direct sulfation afforded unwanted 3-O-sulfated (instead of 2-O-sulfated) iduronic acid residues, a strategy involving graded solvolytic desulfation of chemically oversulfated C5-epimerized sulfaminoheparosans was assessed using persulfated heparin and heparan sulfate as model compounds. The O-desulfation **process** was shown to increase the anti-factor Xa activity of oversulfated heparin.